ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Dr. Arlene O. Siefker-Radtke on Neoadjuvant Chemotherapy Plus Surgery in Bladder Cancer

Arlene O. Siefker-Radtke, MD
Published Online:11:52 AM, Thu February 18, 2016

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the pairing of neoadjuvant chemotherapy and surgery in patients with bladder cancer. Siefker-Radtke says her preferred mathod of neoadjuvant chemotherapy is doxorubicin plus ifosfamide with an alternating regimen of etoposide cisplatin.

Siefker-Radtke says this particular regimen, followed by surgery, tends to fare much better than surgery alone. She adds that surgery plus non-neoadjuvant chemotherapy also does not fare well in comparison.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.